Drug intelligence / Profile preview

AP20

Development stage: Preclinical
Lead developer: Aprogen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AP20 is a novel monoclonal antibody being developed by Aprogen for the treatment of osteoarthritis. It is part of the company's pipeline of novel biologics created using their proprietary antibody-based platform technology. While the specific molecular target of AP20 has not been publicly disclosed, the drug is intended to address the therapeutic needs of patients with degenerative joint disease. It is currently in the early stages of development, utilizing Aprogen's specialized antibody engineering capabilities.

Beyond the preview

Go deeper on AP20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP20.

Explore the full profile